Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insignis Receives FDA Fast Track Designation For IN-001 in Anaphylaxis Treatment
Details : IN-001 is a sublingual spray that utilizes an FDA-approved epinephrine prodrug, allowing for rapid administration without needles. It is being evaluated for the treatment of anaphylaxis.
Product Name : IN-001
Product Type : Hormone
Upfront Cash : Inapplicable
August 13, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insignis Therapeutics Announces Positive Results from IN-001 Study For Anaphylaxis
Details : IN-001 (epinephrine) is an adrenergic receptor agonist, small molecule drug candidate which is being evaluated for the treatment of anaphylaxis.
Product Name : IN-001
Product Type : Hormone
Upfront Cash : Inapplicable
July 10, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insignis Therapeutics Receives FDA Feedback for Needle-Free Treatment
Details : IN-001 is a sublingual spray that utilizes an FDA-approved epinephrine prodrug, allowing for rapid administration without needles. It is being evaluated for the treatment of anaphylaxis.
Product Name : IN-001
Product Type : Hormone
Upfront Cash : Inapplicable
May 11, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : HLK Pharmacin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 single dose study in healthy volunteers will compare IN-001 orally dissolving tablet (epinephrine prodrug) vs the current standard of care, EPIPEN (epinephrine injection).
Product Name : IN-001
Product Type : Hormone
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : HLK Pharmacin
Deal Size : Inapplicable
Deal Type : Inapplicable